Characterization of cationic liposomes having IL-2 expressed on their external surface, and their affinity to cervical cancer cells expressing the IL-2 receptor

Journal of Drug Targeting

Volumn 17, Issue 7, 2009, Pages 496-501

  Corona Ortega, Teresa ^a   Rangel Corona, Rosalva ^a   Hernández Jiménez, Miriam ^a   Baeza, Isabel ^b   Ibáñez, Miguel ^b   Weiss Steider, Benny ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Cationic liposomes; Cervical cancer; IL 2 liposomes; IL 2 receptor

Indexed keywords

ANION; CATION; CHOLESTEROL; CHOLESTERYLSPERMIDINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; SPERMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; SPERMIDINE;

ARTICLE; CANCER CELL CULTURE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ANIONS; ANTINEOPLASTIC AGENTS; CATIONS; CELL LINE, TUMOR; CHOLESTEROL; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERLEUKIN-2; LIPOSOMES; RECEPTORS, INTERLEUKIN-2; SPERMIDINE; UTERINE CERVICAL NEOPLASMS;

EID: 70349785540     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860903012810     Document Type: Article

References (22)

1. Bao A, Phillips W, Goins B, Zheng X, Sabour S, Natarajan M, Woolley F, Zavaleta C, Otto R. (2006). Potential use of drug carried- liposomes for cancer therapy via direct intratumoral injection. Int J Pharm, 316: 162-169.
2. Barba D, Saris S, Holder C, Rosenberg S, Oldfield E. (1989). Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg, 70: 175-182.
3. Bien E, Balcerska A. (2008). Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 13: 1-26.
4. Cullis P., Hope M. (1985). Physical properties and functional roles of lipids in membranes. In: Vance, D., Vance, J., ed. Biochemistry of lipids and membranes. Vancouver: The Benjamin/Cummings Publishing Company INC, p48.
5. Fahr A, van Hoogevest P, May S, Bergstrand N, Leigh M. (2005). Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci, 26: 251-265.
6. Gandolfi L, Solmi L, Pizza G, Bertoni F, Muratori R, De Vinci C, Bacchini P, Morelli M, Corrado G. (1989). Intratumoral echo-guided injection of interleukin-2 and lymphokine-activated killer cells in hepatocellular carcinoma. Hepatogastroenterology, 36: 352-356.
7. Ibáñez M, Gariglio P, Chávez P, Santiago R, Wong C, Baeza I. (1996). Spermidine-condensed DNA and cone-shaped lipids improve delivery and expression of exogenous DNA transfer by liposomes. Biochem Cell Biol, 74: 633-643.
8. Kepczyński M, Nawalany K, Kumorek M, Kobierska A, Jachimska B, Nowakowska M. (2008). Which physical and structural factors of liposome carriers control their drug-loading efficiency? Chem Phys Lipids, 155: 7-15.
9. Kondapaneni M, McGregor J, Salvemini D, Laubach V, Samlowski W. (2008). Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice. J Immunother, 31: 325-333.
10. Konigsberg P, Godtel R, Kissel T, Richer L. (1998). The development of IL-2 conjugated liposomes for therapeutic purposes. Biochim Biophys Acta, 1370: 243-251.
11. Lian T, Ho RJ. (2001). Trends and developments in liposome drug delivery systems. J Pharm Sci, 90: 667-680.
12. Mule J, Shu S, Rosenberg S. (1985). The anti-tumor efficacy of lymphokine- activated killer cells and recombinant interleukin 2 in vivo. J Immunol, 135: 646-652. (Pubitemid 15012440)
13. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg S, Childs R, Restifo N. (2006). Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol, 3: 668-681.
14. Neville M, Boni L, Pflug L, Popescu M, Robb R. (2000). Biopharmaceutics of liposomal interleukin 2, Oncolipin. Cytokine, 12: 1691-1701.
15. Pellequer Y, Ollivon M, Barratt G. (2004) Formulation of liposomes associated with recombinant interleukin-2: effect on interleukin- 2 activity. Biomed Pharmacother, 58: 162-167.
16. Podo F. (1975). The application of nuclear magnetic resonance spectroscopy to the study of natural and model membranes. Biochimie, 57: 461-469.
17. Rangel R, Rodríguez L, Flores G, Gomez C, Soto I, Mendoza F, Weiss B. (1998). Differential expression of the two components of the interleukin- 2 receptor in cervical cancer cells. In: Moraes M, Brentani R, Bevlacqua R, Eds. Proceedings of the 17th International Cancer Congress (pp. 1239-1243). Italy: Monduzzi Editore.
18. Rosenberg S., Lotze M., Muul L., Chang A., Avis F., Leitman S., Linehan W., Robertson C., Lee R., Rubin J., Seipp C., Simpson C., White D. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated. N Engl J Med 316: 889-897.
19. Shirai M, Watanabe S, Nishioka M. (1990). Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report. Eur J Cancer, 26: 1045-1048.
20. Szoka F, Papahadjopoulus D. (1980). Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann Rev Biophys Bioeng, 9: 467-508.
21. Ulrich A. (2002). Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep, 22: 129-150
22. Vial T, Descotes J. (1992). Clinical toxicity of interleukin-2. Drug Saf, 7: 417-433.